Long-term administration of rapamycin reduces adiposity, but impairs glucose tolerance in high-fat diet-fed KK/HlJ mice

Basic and Clinical Pharmacology and Toxicology

Volumn 105, Issue 3, 2009, Pages 188-198

  Chang, Geng Ruei ^a   Wu, Ying Ying ^a   Chiu, Yi Shin ^a   Chen, Wen Ying ^a   Liao, Jiunn Wang ^a   Hsu, Hong Ming ^a   Chao, Te Hsin ^a,b   Hung, Siu Wan ^a,b   Mao, Frank Chiahung ^a  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG VEHICLE; INSULIN; LEPTIN; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; REACTIVE OXYGEN METABOLITE; S6 KINASE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL SIZE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; EPIDIDYMIS FAT; FATTY LIVER; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; INSULIN BLOOD LEVEL; LIPID DIET; LONG TERM CARE; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RETROPERITONEAL FAT; WEIGHT GAIN;

ADIPOCYTES; ADIPOSE TISSUE, WHITE; ADIPOSITY; ANIMALS; BODY WEIGHT; DIETARY FATS; EATING; GLUCOSE; GLUCOSE TOLERANCE TEST; IMMUNOSUPPRESSIVE AGENTS; INSULIN; LEPTIN; MALE; MICE; OBESITY; SIROLIMUS;

ANIMALIA; MUS;

EID: 68949215897     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2009.00427.x     Document Type: Article

References (67)

1. Cota D, Proulx K, Smith KA, Kozma SC, Thomas G, Woods SC et al. Hypothalamic mTOR signaling regulates food intake. Science 2006 312 : 927 930.
2. Dann SG, Selvaraj A, Thomas G. mTOR ComplepagerangeK1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol Med 2007 13 : 252 259.
3. Manning BD. Balancing Akt with S6 K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 2004 167 : 399 403.
4. Khamzina L, Veilleux A, Bergeron S, Marette A. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. Endocrinology 2005 146 : 1473 1481.
5. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000 351 : 95 105.
6. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994 369 : 756 758.
7. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998 31 : 335 340.
8. Cowan PA, Heizer KE. Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection. Nephrol Nurs J 2000 27 : 623 625.
9. Morrisett JD, Abdel-Fattah G., Kahan BD. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant Proc 2003 35 : S143 S150.
10. Garber K. Rapamycin's resurrection: a new way to target the cancer cell cycle. J Natl Cancer Inst 2001 93 : 1517 1519.
11. Thomas GV. mTOR and cancer: reason for dancing at the crossroads? Curr Opin Genet Dev 2006 16 : 78 84.
12. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2004 349 : 1315 1323.
13. Serruys PW, Regar E, Carter AJ. Rapamycin eluting stent: the onset of a new era in interventional cardiology. Heart 2002 87 : 305 307.
14. Lo A. Immunosuppression and metabolic syndrome in renal transplant recipients. Metab Syndr Relat Disord 2004 2 : 263 273.
15. Soliman GA. The mammalian target of rapamycin signaling network and gene regulation. Curr Opin Lipidol 2005 16 : 317 323.
16. Bodary PF, Vargas FB, King SA, Jongeward KL, Wickenheiser KJ, Eitzman DT. Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance. J Thromb Haemost 2005 3 : 2149 2153.
17. Suto J, Matsuura S, Imamura K, Yamanaka H, Sekikawa K. Genetic analysis of non-insulin-dependent diabetes mellitus in KK and KK-Ay mice. Eur J Endocrinol 1998 39 : 654 661.
18. Chen WY, Chen CJ, Liu CH, Mao FC. Chromium supplementation enhances insulin signalling in skeletal muscle of obese KK/HIJ diabetic mice. Diabetes Obes Metab 2009 11 : 293 303.
19. Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide KL, Sarkaria JN. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res 2002 15 : 7291 7297.
20. Namba R, Young LJ, Abbey CK, Kim L, Damonte P, Borowsky AD et al. Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ. Clin Cancer Res 2006 12 : 2613 2621.
21. Shioi T, McMullen JR, Tarnavski O, Converso K, Sherwood MC, Manning WJ et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 2003 107 : 1664 1670.
22. Kwon YS, Hong HS, Kim JC, Shin JS, Son Y. Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo. Invest Ophthalmol Vis Sci 2005 46 : 454 460.
23. Chodera A, Feller K. Some aspects of pharmacokinetic and biotransformation differences in humans and mammal animals. Int J Clin Pharmacol Biopharm 1978 16 : 357 360.
24. Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: a review of the evidence. Kidney Int 2001 59 : 3 16.
25. Chen YB, Sun YA, Gong JP. Effects of rapamycin in liver transplantation. Hepatobiliary Pancreat Dis Int 2008 7 : 25 28.
26. Cornelli U, Terranova R, Luca S, Cornelli M, Alberti A. Bioavailability and antioxidant activity of some food supplements in men and women using the D-Roms test as a marker of oxidative stress. J Nutr 2001 131 : 3208 3211.
27. Folch J, Lees M, Stanley GHS. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957 226 : 497 509.
28. Bluher M, Wilson-Fritch L, Leszyk J, Laustsen PG, Corvera S, Kahn CR. Role of insulin action and cell size on protein expression patterns in adipocytes. J Biol Chem 2004 279 : 31902 31909.
29. Gilat T, Leikin-Frenkel A, Goldiner I, Juhel C, Lafont H, Gobbi D et al. Prevention of diet-induced fatty liver in experimental animals by the oral administration of a fatty acid bile acid conjugate (FABAC). Hepatology 2003 38 : 436 442.
30. Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell 2007 12 : 487 502.
31. Cota D, Matter EK, Woods SC, Seeley RJ. The role of hypothalamic mammalian target of rapamycin complex 1 signaling in diet-induced obesity. J Neurosci 2008 28 : 7202 7208.
32. Heid HW, Moll R, Schwetlick I, Rackwitz HR, Keenan TW. Adipophilin is a specific marker of lipid accumulation in diverse cell types and diseases. Cell Tissue Res 1998 294 : 309 321.
33. Larigauderie G, Cuaz-Pérolin C, Younes AB, Furman C, Lasselin C, Copin C et al. Adipophilin increases triglyceride storage in human macrophages by stimulation of biosynthesis and inhibition of β-oxidation. FEBS J 2006 273 : 3498 3510.
34. Chang BH, Li L, Paul A, Taniguchi S, Nannegari V, Heird WC et al. Protection against fatty liver but normal adipogenesis in mice lacking adipose differentiation-related protein. Mol Cell Biol 2006 26 : 1063 1076.
35. Larigauderie G, Furman C, Jaye M, Lasselin C, Copin C, Fruchart JC et al. Adipophilin enhances lipid accumulation and prevents lipid efflux from THP-1 macrophages: potential role in atherogenesis. Arterioscler Thromb Vasc Biol 2004 24 : 504 510.
36. Sipula IJ, Brown NF, Perdomo G. Rapamycin-mediated inhibition of mammalian target of rapamycin in skeletal muscle cells reduces glucose utilization and increases fatty acid oxidation. Metabolism 2006 55 : 1637 1644.
37. Newberry EP, Xie Y, Kennedy SM, Luo J, Davidson NO. Protection against Western diet-induced obesity and hepatic steatosis in liver fatty acid-binding protein knockout mice. Hepatology 2006 44 : 1191 1205.
38. Westerbacka J, Lammi K, Hakkinen AM, Rissanen A, Salminen I, Aro A et al. Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab 2005 90 : 2804 2809.
39. Mine T, Miura K, Kajioka T, Kitahara Y. Nateglinide prevents fatty liver through up-regulation of lipid oxidation pathway in Goto-Kakizaki rats on a high-fat diet. Metabolism 2008 57 : 140 148.
40. Schieke SM, Phillips D, McCoy JPJr, Aponte AM, Shen RF, Balaban RS et al. The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. J Biol Chem 2006 281 : 27643 27652.
41. Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puigserver P. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 2007 450 : 736 740.
42. Mauvoisin D, Rocque G, Arfa O, Radenne A, Boissier P, Mounier C. Role of the PI3-kinase/mTor pathway in the regulation of the stearoyl CoA desaturase (SCD1) gene expression by insulin in liver. J Cell Commun Signal 2007 1 : 113 125.
43. Imai Y, Varela GM, Jackson MB, Graham MJ, Crooke RM, Ahima RS. Reduction of hepatosteatosis and lipid levels by an adipose differentiation-related protein antisense oligonucleotide. Gastroenterology 2007 132 : 1947 1954.
44. Rosenbaum M, Leibel RL, Hirsch J. Obesity. N Engl J Med 1997 337 : 396 407.
45. Schwartz MW, Woods SC, Porte D Jr., Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000 404 : 661 671.
46. Della Zuana O, Sadlo M, Germain M, Félétou M, Chamorro S, Tisserand F et al. Reduced food intake in response to CGP 71683A may be due to mechanisms other than NPY Y5 receptor blockade. Int J Obes 2001 25 : 84 94.
47. Villafuerte BC, Fine JB, Bai Y, Zhao W, Fleming S, DiGirolamo M. Expressions of leptin and insulin-like growth factor-I are highly correlated and region-specific in adipose tissue of growing rats. Obes Res 2000 8 : 646 655.
48. Baeder WL, Sredy J, Sehgal SN, Chang JY, Adams LM. Rapamycin prevents the onset of insulin-dependent diabetes mellitus (IDDM) in NOD mice. Clin Exp Immunol 1992 89 : 174 178.
49. Briaud I, Dickson LM, Lingohr MK, McCuaig JF, Lawrence JC, Rhodes CJ. Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase B-mediated signaling pathway in β-cells. J Biol Chem 2005 280 : 2282 2293.
50. Tzatsos A, Kandror KV. Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol Cell Biol 2006 26 : 63 76.
51. Pende M, Kozma SC, Jaquet M, Oorschot V, Burcelin R, Le Marchand-Brustel Y et al. Hypoinsulinaemia, glucose intolerance and diminished β-cell size in S6K1-deficient mice. Nature 2000 408 : 994 997.
52. Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 2004 431 : 200 205.
53. Chang GR, Chiu YS, Wu YY, Chen WY, Liao JW, Chao TH et al. Rapamycin protects against high fat diet-induced obesity in C57BL/6J mice. J Pharmacol Sci 2009 109 : 496 503.
54. Fraenkel M, Ketzinel-Gilad M, Ariav Y, Pappo O, Karaca M, Castel J et al. mTOR inhibition by rapamycin prevents β-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 2008 57 : 945 957.
55. Di Paolo S, Teutonico A, Leogrande D, Capobianco C, Schena PF. Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: A crossroad between cancer and diabetes? J Am Soc Nephrol 2006 17 : 2236 2244.
56. Dandona P, Mohanty P, Ghanim H, Aljada A, Browne R, Hamouda W et al. The suppressive effect of dietary restriction and weight loss in the obese on the generation of reactive oxygen species by leukocytes, lipid peroxidation, and protein carbonylation. J Clin Endocrinol Metab 2001 86 : 355 362.
57. McClung JP, Roneker CA, Mu W, Lisk DJ, Langlais P, Liu F et al. Development of insulin resistance and obesity in mice overexpressing cellular glutathione peroxidase. Proc Natl Acad Sci USA 2004 101 : 8852 8857.
58. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004 114 : 1752 1761.
59. Mauriège P, Imbeault P, Langin D, Lacaille M, Alméras N, Tremblay A et al. Regional and gender variations in adipose tissue lipolysis in response to weight loss. J Lipid Res 1999 40 : 1559 1571.
60. Medina J, Fernández-Salazar LI, García-Buey L, Moreno-Otero R. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care 2004 27 : 2057 2066.
61. Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Metab 2000 85 : 2970 2973.
62. Welle S, Lilavivathana, U, Campbell RG. Increased plasma norepinephrine concentrations and metabolic rates following glucose ingestion in man. Metabolism 1980 29 : 806 809.
63. Alsharif NZ, Hassoun EA. Protective effects of vitamin A and vitamin E succinate against 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced body wasting, hepatomegaly, thymic atrophy, production of reactive oxygen species and DNA damage in C57BL/6J mice. Basic Clin Pharmacol Toxicol 2004 95 : 131 138.
64. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002 23 : 599 622.
65. Rösen P, Nawroth PP, King G, Möller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 2001 17 : 189 212.
66. Mathis AS, Dave N, Knipp GT, Friedman GS. Drug-related dyslipidemia after renal transplantation. Am J Health Syst Pharm 2004 61 : 565 585.
67. Reuben A. Long-term management of the liver transplant patient: diabetes, hyperlipidemia, and obesity. Liver Transpl 2001 7 : S13 S21.